Alpine Immune Sciences is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative, protein-based immunotherapies targeting the immune synapse to treat cancer and autoimmune and inflammatory diseases. The Company’s platform converts native immune system proteins into multi-targeted therapeutics potentially capable of modulating the human immune system. The Company’s lead program, ALPN-101, is a dual ICOS and CD28 antagonist intended for autoimmune and inflammatory diseases. CD28 and ICOS are closely related costimulatory molecules with partially overlapping roles in T cell activation likely playing a role in multiple autoimmune and inflammatory diseases. The Company’s lead oncology program, ALPN-202, is a conditional CD28 costimulator and dual checkpoint inhibitor.